#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=In 2030 , in Western Europe and in the ten most populous nations of the world , the estimated number of individuals with Parkinson ’s disease ( PD ) will be over 8 million .
2-1	16-18	In	_	_	_	_
2-2	19-23	2030	time[2]	new[2]	_	_
2-3	24-25	,	time[2]	new[2]	_	_
2-4	26-28	in	time[2]	new[2]	_	_
2-5	29-36	Western	time[2]|place[3]	new[2]|new[3]	_	_
2-6	37-43	Europe	time[2]|place[3]	new[2]|new[3]	_	_
2-7	44-47	and	time[2]	new[2]	_	_
2-8	48-50	in	time[2]	new[2]	_	_
2-9	51-54	the	time[2]|place[4]	new[2]|new[4]	_	_
2-10	55-58	ten	time[2]|place[4]	new[2]|new[4]	_	_
2-11	59-63	most	time[2]|place[4]	new[2]|new[4]	_	_
2-12	64-72	populous	time[2]|place[4]	new[2]|new[4]	_	_
2-13	73-80	nations	time[2]|place[4]	new[2]|new[4]	_	_
2-14	81-83	of	time[2]|place[4]	new[2]|new[4]	_	_
2-15	84-87	the	time[2]|place[4]|place[5]	new[2]|new[4]|new[5]	_	_
2-16	88-93	world	time[2]|place[4]|place[5]	new[2]|new[4]|new[5]	_	_
2-17	94-95	,	_	_	_	_
2-18	96-99	the	abstract[6]	new[6]	_	_
2-19	100-109	estimated	abstract[6]	new[6]	_	_
2-20	110-116	number	abstract[6]	new[6]	_	_
2-21	117-119	of	abstract[6]	new[6]	_	_
2-22	120-131	individuals	abstract[6]|person[7]	new[6]|new[7]	_	_
2-23	132-136	with	abstract[6]|person[7]	new[6]|new[7]	_	_
2-24	137-146	Parkinson	abstract[6]|person[7]|person[8]|abstract[9]	new[6]|new[7]|new[8]|new[9]	appos|coref|appos|coref	2-28[0_9]|7-17[54_8]|2-28[0_9]|7-17[54_8]
2-25	147-149	’s	abstract[6]|person[7]|person[8]|abstract[9]	new[6]|new[7]|new[8]|new[9]	_	_
2-26	150-157	disease	abstract[6]|person[7]|abstract[9]	new[6]|new[7]|new[9]	_	_
2-27	158-159	(	_	_	_	_
2-28	160-162	PD	abstract	giv	coref	4-26[24_0]
2-29	163-164	)	_	_	_	_
2-30	165-169	will	_	_	_	_
2-31	170-172	be	_	_	_	_
2-32	173-177	over	quantity[11]	new[11]	_	_
2-33	178-179	8	quantity[11]	new[11]	_	_
2-34	180-187	million	quantity[11]	new[11]	_	_
2-35	188-189	.	_	_	_	_

#Text=One of the main challenges to be faced will be the development of technological and cost-effective solutions to improve the healthcare of these patients .
3-1	190-193	One	abstract[12]	new[12]	coref	3-11[14_12]
3-2	194-196	of	abstract[12]	new[12]	_	_
3-3	197-200	the	abstract[12]|abstract[13]	new[12]|new[13]	coref	14-6[118_13]
3-4	201-205	main	abstract[12]|abstract[13]	new[12]|new[13]	_	_
3-5	206-216	challenges	abstract[12]|abstract[13]	new[12]|new[13]	_	_
3-6	217-219	to	_	_	_	_
3-7	220-222	be	_	_	_	_
3-8	223-228	faced	_	_	_	_
3-9	229-233	will	_	_	_	_
3-10	234-236	be	_	_	_	_
3-11	237-240	the	abstract[14]	giv[14]	_	_
3-12	241-252	development	abstract[14]	giv[14]	_	_
3-13	253-255	of	abstract[14]	giv[14]	_	_
3-14	256-269	technological	abstract[14]|abstract[15]	giv[14]|new[15]	coref	16-15[148_15]
3-15	270-273	and	abstract[14]|abstract[15]	giv[14]|new[15]	_	_
3-16	274-288	cost-effective	abstract[14]|abstract[15]	giv[14]|new[15]	_	_
3-17	289-298	solutions	abstract[14]|abstract[15]	giv[14]|new[15]	_	_
3-18	299-301	to	_	_	_	_
3-19	302-309	improve	_	_	_	_
3-20	310-313	the	abstract[16]	new[16]	coref	13-46[0_16]
3-21	314-324	healthcare	abstract[16]	new[16]	_	_
3-22	325-327	of	abstract[16]	new[16]	_	_
3-23	328-333	these	abstract[16]|person[17]	new[16]|new[17]	coref	13-34[113_17]
3-24	334-342	patients	abstract[16]|person[17]	new[16]|new[17]	_	_
3-25	343-344	.	_	_	_	_

#Text=Remote medical communications , for example in the form of telemedicine and decentralized care pathways , will inevitably become part of the clinical management of such disease .
4-1	345-351	Remote	abstract[18]	new[18]	_	_
4-2	352-359	medical	abstract[18]	new[18]	_	_
4-3	360-374	communications	abstract[18]	new[18]	_	_
4-4	375-376	,	abstract[18]	new[18]	_	_
4-5	377-380	for	abstract[18]	new[18]	_	_
4-6	381-388	example	abstract[18]	new[18]	_	_
4-7	389-391	in	abstract[18]	new[18]	_	_
4-8	392-395	the	abstract[18]|abstract[19]	new[18]|new[19]	_	_
4-9	396-400	form	abstract[18]|abstract[19]	new[18]|new[19]	_	_
4-10	401-403	of	abstract[18]|abstract[19]	new[18]|new[19]	_	_
4-11	404-416	telemedicine	abstract[18]|abstract[19]|abstract	new[18]|new[19]|new	_	_
4-12	417-420	and	abstract[18]|abstract[19]	new[18]|new[19]	_	_
4-13	421-434	decentralized	abstract[18]|abstract[19]|abstract[22]	new[18]|new[19]|new[22]	_	_
4-14	435-439	care	abstract[18]|abstract[19]|abstract|abstract[22]	new[18]|new[19]|new|new[22]	_	_
4-15	440-448	pathways	abstract[18]|abstract[19]|abstract[22]	new[18]|new[19]|new[22]	_	_
4-16	449-450	,	_	_	_	_
4-17	451-455	will	_	_	_	_
4-18	456-466	inevitably	_	_	_	_
4-19	467-473	become	_	_	_	_
4-20	474-478	part	_	_	_	_
4-21	479-481	of	_	_	_	_
4-22	482-485	the	abstract[23]	new[23]	_	_
4-23	486-494	clinical	abstract[23]	new[23]	_	_
4-24	495-505	management	abstract[23]	new[23]	_	_
4-25	506-508	of	abstract[23]	new[23]	_	_
4-26	509-513	such	abstract[23]|abstract[24]	new[23]|giv[24]	coref	7-20[0_24]
4-27	514-521	disease	abstract[23]|abstract[24]	new[23]|giv[24]	_	_
4-28	522-523	.	_	_	_	_

#Text=Among the tougher hurdles to overcome , there is the accurate , low-cost and objective quantification of the typical motor symptoms , which is a key issue for obtaining a complete indication of the patient ’s state of impairment .
5-1	524-529	Among	_	_	_	_
5-2	530-533	the	abstract[25]	new[25]	coref	16-7[145_25]
5-3	534-541	tougher	abstract[25]	new[25]	_	_
5-4	542-549	hurdles	abstract[25]	new[25]	_	_
5-5	550-552	to	_	_	_	_
5-6	553-561	overcome	_	_	_	_
5-7	562-563	,	_	_	_	_
5-8	564-569	there	_	_	_	_
5-9	570-572	is	_	_	_	_
5-10	573-576	the	abstract[26]	new[26]	_	_
5-11	577-585	accurate	abstract[26]	new[26]	_	_
5-12	586-587	,	abstract[26]	new[26]	_	_
5-13	588-596	low-cost	abstract[26]	new[26]	_	_
5-14	597-600	and	abstract[26]	new[26]	_	_
5-15	601-610	objective	abstract[26]	new[26]	_	_
5-16	611-625	quantification	abstract[26]	new[26]	_	_
5-17	626-628	of	abstract[26]	new[26]	_	_
5-18	629-632	the	abstract[26]|abstract[28]	new[26]|new[28]	coref	7-36[60_28]
5-19	633-640	typical	abstract[26]|abstract[28]	new[26]|new[28]	_	_
5-20	641-646	motor	abstract[26]|object|abstract[28]	new[26]|new|new[28]	coref	6-6
5-21	647-655	symptoms	abstract[26]|abstract[28]	new[26]|new[28]	_	_
5-22	656-657	,	_	_	_	_
5-23	658-663	which	_	_	_	_
5-24	664-666	is	_	_	_	_
5-25	667-668	a	abstract[29]	new[29]	coref	24-17[258_29]
5-26	669-672	key	abstract[29]	new[29]	_	_
5-27	673-678	issue	abstract[29]	new[29]	_	_
5-28	679-682	for	_	_	_	_
5-29	683-692	obtaining	_	_	_	_
5-30	693-694	a	abstract[30]	new[30]	_	_
5-31	695-703	complete	abstract[30]	new[30]	_	_
5-32	704-714	indication	abstract[30]	new[30]	_	_
5-33	715-717	of	abstract[30]	new[30]	_	_
5-34	718-721	the	abstract[30]|abstract[32]	new[30]|new[32]	_	_
5-35	722-729	patient	abstract[30]|person[31]|abstract[32]	new[30]|new[31]|new[32]	coref	11-28[94_31]
5-36	730-732	’s	abstract[30]|person[31]|abstract[32]	new[30]|new[31]|new[32]	_	_
5-37	733-738	state	abstract[30]|abstract[32]	new[30]|new[32]	_	_
5-38	739-741	of	abstract[30]|abstract[32]	new[30]|new[32]	_	_
5-39	742-752	impairment	abstract[30]|abstract[32]|abstract	new[30]|new[32]|new	coref	9-29
5-40	753-754	.	_	_	_	_

#Text=Since 1967 , when the motor effects of Levodopa ( LD ) on bradykinesia have been shown for the first time in a video , the way has been traced towards the quantification of movement disorders and their therapeutic response .
6-1	755-760	Since	_	_	_	_
6-2	761-765	1967	time	new	_	_
6-3	766-767	,	_	_	_	_
6-4	768-772	when	_	_	_	_
6-5	773-776	the	abstract[36]	new[36]	_	_
6-6	777-782	motor	object|abstract[36]	giv|new[36]	coref	12-15
6-7	783-790	effects	abstract[36]	new[36]	_	_
6-8	791-793	of	abstract[36]	new[36]	_	_
6-9	794-802	Levodopa	abstract[36]|substance	new[36]|new	appos	6-11
6-10	803-804	(	abstract[36]	new[36]	_	_
6-11	805-807	LD	abstract[36]|substance	new[36]|giv	_	_
6-12	808-809	)	abstract[36]	new[36]	_	_
6-13	810-812	on	abstract[36]	new[36]	_	_
6-14	813-825	bradykinesia	abstract[36]|abstract	new[36]|new	coref	14-35
6-15	826-830	have	_	_	_	_
6-16	831-835	been	_	_	_	_
6-17	836-841	shown	_	_	_	_
6-18	842-845	for	_	_	_	_
6-19	846-849	the	abstract[40]	new[40]	coref	12-5[0_40]
6-20	850-855	first	abstract[40]	new[40]	_	_
6-21	856-860	time	abstract[40]	new[40]	_	_
6-22	861-863	in	abstract[40]	new[40]	_	_
6-23	864-865	a	abstract[40]|abstract[41]	new[40]|new[41]	coref	23-16[243_41]
6-24	866-871	video	abstract[40]|abstract[41]	new[40]|new[41]	_	_
6-25	872-873	,	_	_	_	_
6-26	874-877	the	abstract[42]	new[42]	_	_
6-27	878-881	way	abstract[42]	new[42]	_	_
6-28	882-885	has	_	_	_	_
6-29	886-890	been	_	_	_	_
6-30	891-897	traced	_	_	_	_
6-31	898-905	towards	_	_	_	_
6-32	906-909	the	abstract[43]	new[43]	_	_
6-33	910-924	quantification	abstract[43]	new[43]	_	_
6-34	925-927	of	abstract[43]	new[43]	_	_
6-35	928-936	movement	abstract[43]|abstract|abstract[45]|abstract[46]	new[43]|new|new[45]|new[46]	coref|coref|coref|coref|coref|coref	8-28|8-29[0_45]|8-28|8-29[0_45]|8-28|8-29[0_45]
6-36	937-946	disorders	abstract[43]|abstract[45]|abstract[46]	new[43]|new[45]|new[46]	_	_
6-37	947-950	and	abstract[43]|abstract[46]	new[43]|new[46]	_	_
6-38	951-956	their	abstract[43]|abstract[46]|abstract[47]	new[43]|new[46]|new[47]	_	_
6-39	957-968	therapeutic	abstract[43]|abstract[46]|abstract[47]	new[43]|new[46]|new[47]	_	_
6-40	969-977	response	abstract[43]|abstract[46]|abstract[47]	new[43]|new[46]|new[47]	_	_
6-41	978-979	.	_	_	_	_

#Text=This pathway passes through semi-quantitative rating scales , such as the Hoehn and Yahr stage and unified Parkinson ’s disease rating scale ( UPDRS ) , which is still the gold standard scale for assessing symptoms in PD .
7-1	980-984	This	abstract[48]	new[48]	_	_
7-2	985-992	pathway	abstract[48]	new[48]	_	_
7-3	993-999	passes	_	_	_	_
7-4	1000-1007	through	_	_	_	_
7-5	1008-1025	semi-quantitative	abstract[50]	new[50]	coref	11-8[89_50]
7-6	1026-1032	rating	abstract|abstract[50]	new|new[50]	coref	7-21
7-7	1033-1039	scales	abstract[50]	new[50]	_	_
7-8	1040-1041	,	abstract[50]	new[50]	_	_
7-9	1042-1046	such	abstract[50]	new[50]	_	_
7-10	1047-1049	as	abstract[50]	new[50]	_	_
7-11	1050-1053	the	abstract[50]|abstract[53]	new[50]|new[53]	_	_
7-12	1054-1059	Hoehn	abstract[50]|abstract|abstract[53]	new[50]|new|new[53]	_	_
7-13	1060-1063	and	abstract[50]|abstract[53]	new[50]|new[53]	_	_
7-14	1064-1068	Yahr	abstract[50]|person|abstract[53]	new[50]|new|new[53]	_	_
7-15	1069-1074	stage	abstract[50]|abstract[53]	new[50]|new[53]	_	_
7-16	1075-1078	and	_	_	_	_
7-17	1079-1086	unified	person[54]|abstract[57]	giv[54]|new[57]	appos|appos	7-24[0_57]|7-24[0_57]
7-18	1087-1096	Parkinson	person[54]|abstract[57]	giv[54]|new[57]	_	_
7-19	1097-1099	’s	person[54]|abstract[57]	giv[54]|new[57]	_	_
7-20	1100-1107	disease	abstract|abstract[57]	giv|new[57]	coref	7-38
7-21	1108-1114	rating	abstract|abstract[57]	giv|new[57]	_	_
7-22	1115-1120	scale	abstract[57]	new[57]	_	_
7-23	1121-1122	(	_	_	_	_
7-24	1123-1128	UPDRS	abstract	giv	coref	7-29[59_0]
7-25	1129-1130	)	_	_	_	_
7-26	1131-1132	,	_	_	_	_
7-27	1133-1138	which	_	_	_	_
7-28	1139-1141	is	_	_	_	_
7-29	1142-1147	still	abstract[59]	giv[59]	coref	8-4[0_59]
7-30	1148-1151	the	abstract[59]	giv[59]	_	_
7-31	1152-1156	gold	abstract[59]	giv[59]	_	_
7-32	1157-1165	standard	abstract[59]	giv[59]	_	_
7-33	1166-1171	scale	abstract[59]	giv[59]	_	_
7-34	1172-1175	for	_	_	_	_
7-35	1176-1185	assessing	_	_	_	_
7-36	1186-1194	symptoms	abstract[60]	giv[60]	coref	10-16[82_60]
7-37	1195-1197	in	abstract[60]	giv[60]	_	_
7-38	1198-1200	PD	abstract[60]|abstract	giv[60]|giv	coref	13-11
7-39	1201-1202	.	_	_	_	_

#Text=Evaluation through the UPDRS score is a subjective process that comes after a global clinical judgment for the diagnosis in which the experience of the specialist in movement disorders is crucial .
8-1	1203-1213	Evaluation	abstract[62]	new[62]	coref	8-7[65_62]
8-2	1214-1221	through	abstract[62]	new[62]	_	_
8-3	1222-1225	the	abstract[62]|abstract[64]	new[62]|new[64]	_	_
8-4	1226-1231	UPDRS	abstract[62]|abstract|abstract[64]	new[62]|giv|new[64]	coref	18-52
8-5	1232-1237	score	abstract[62]|abstract[64]	new[62]|new[64]	_	_
8-6	1238-1240	is	_	_	_	_
8-7	1241-1242	a	abstract[65]	giv[65]	coref	9-1[72_65]
8-8	1243-1253	subjective	abstract[65]	giv[65]	_	_
8-9	1254-1261	process	abstract[65]	giv[65]	_	_
8-10	1262-1266	that	_	_	_	_
8-11	1267-1272	comes	_	_	_	_
8-12	1273-1278	after	_	_	_	_
8-13	1279-1280	a	abstract[66]	new[66]	coref	9-24[76_66]
8-14	1281-1287	global	abstract[66]	new[66]	_	_
8-15	1288-1296	clinical	abstract[66]	new[66]	_	_
8-16	1297-1305	judgment	abstract[66]	new[66]	_	_
8-17	1306-1309	for	abstract[66]	new[66]	_	_
8-18	1310-1313	the	abstract[66]|abstract[67]	new[66]|new[67]	coref	10-4[80_67]
8-19	1314-1323	diagnosis	abstract[66]|abstract[67]	new[66]|new[67]	_	_
8-20	1324-1326	in	_	_	_	_
8-21	1327-1332	which	_	_	_	_
8-22	1333-1336	the	abstract[68]	new[68]	_	_
8-23	1337-1347	experience	abstract[68]	new[68]	_	_
8-24	1348-1350	of	abstract[68]	new[68]	_	_
8-25	1351-1354	the	abstract[68]|person[69]	new[68]|new[69]	coref	11-18[91_69]
8-26	1355-1365	specialist	abstract[68]|person[69]	new[68]|new[69]	_	_
8-27	1366-1368	in	abstract[68]|person[69]	new[68]|new[69]	_	_
8-28	1369-1377	movement	abstract[68]|person[69]|abstract	new[68]|new[69]|giv	coref	17-13[156_0]
8-29	1378-1387	disorders	abstract	giv	_	_
8-30	1388-1390	is	_	_	_	_
8-31	1391-1398	crucial	_	_	_	_
8-32	1399-1400	.	_	_	_	_

#Text=This process is , in fact , characterized by an intrinsic inter-rater variability due to the different experience of the examiners , influencing the final judgment on the impairment severity .
9-1	1401-1405	This	abstract[72]	giv[72]	coref	25-9[264_72]
9-2	1406-1413	process	abstract[72]	giv[72]	_	_
9-3	1414-1416	is	_	_	_	_
9-4	1417-1418	,	_	_	_	_
9-5	1419-1421	in	_	_	_	_
9-6	1422-1426	fact	_	_	_	_
9-7	1427-1428	,	_	_	_	_
9-8	1429-1442	characterized	_	_	_	_
9-9	1443-1445	by	_	_	_	_
9-10	1446-1448	an	abstract[73]	new[73]	_	_
9-11	1449-1458	intrinsic	abstract[73]	new[73]	_	_
9-12	1459-1470	inter-rater	abstract[73]	new[73]	_	_
9-13	1471-1482	variability	abstract[73]	new[73]	_	_
9-14	1483-1486	due	_	_	_	_
9-15	1487-1489	to	_	_	_	_
9-16	1490-1493	the	abstract[74]	new[74]	_	_
9-17	1494-1503	different	abstract[74]	new[74]	_	_
9-18	1504-1514	experience	abstract[74]	new[74]	_	_
9-19	1515-1517	of	abstract[74]	new[74]	_	_
9-20	1518-1521	the	abstract[74]|person[75]	new[74]|new[75]	_	_
9-21	1522-1531	examiners	abstract[74]|person[75]	new[74]|new[75]	_	_
9-22	1532-1533	,	_	_	_	_
9-23	1534-1545	influencing	_	_	_	_
9-24	1546-1549	the	abstract[76]	giv[76]	_	_
9-25	1550-1555	final	abstract[76]	giv[76]	_	_
9-26	1556-1564	judgment	abstract[76]	giv[76]	_	_
9-27	1565-1567	on	abstract[76]	giv[76]	_	_
9-28	1568-1571	the	abstract[76]|abstract[78]	giv[76]|new[78]	_	_
9-29	1572-1582	impairment	abstract[76]|abstract|abstract[78]	giv[76]|giv|new[78]	coref	13-8[107_0]
9-30	1583-1591	severity	abstract[76]|abstract[78]	giv[76]|new[78]	_	_
9-31	1592-1593	.	_	_	_	_

#Text=A percentage of incorrect diagnosis of 25 % has also been reported , especially when symptoms such as essential tremor , vascular parkinsonism and atypical parkinsonian syndromes manifest .
10-1	1594-1595	A	abstract[79]	new[79]	_	_
10-2	1596-1606	percentage	abstract[79]	new[79]	_	_
10-3	1607-1609	of	abstract[79]	new[79]	_	_
10-4	1610-1619	incorrect	abstract[79]|abstract[80]	new[79]|giv[80]	_	_
10-5	1620-1629	diagnosis	abstract[79]|abstract[80]	new[79]|giv[80]	_	_
10-6	1630-1632	of	abstract[79]|abstract[80]	new[79]|giv[80]	_	_
10-7	1633-1635	25	abstract[79]|abstract[80]|quantity[81]	new[79]|giv[80]|new[81]	_	_
10-8	1636-1637	%	abstract[79]|abstract[80]|quantity[81]	new[79]|giv[80]|new[81]	_	_
10-9	1638-1641	has	_	_	_	_
10-10	1642-1646	also	_	_	_	_
10-11	1647-1651	been	_	_	_	_
10-12	1652-1660	reported	_	_	_	_
10-13	1661-1662	,	_	_	_	_
10-14	1663-1673	especially	_	_	_	_
10-15	1674-1678	when	_	_	_	_
10-16	1679-1687	symptoms	abstract[82]	giv[82]	coref	14-10[120_82]
10-17	1688-1692	such	abstract[82]	giv[82]	_	_
10-18	1693-1695	as	abstract[82]	giv[82]	_	_
10-19	1696-1705	essential	abstract[82]|abstract[83]	giv[82]|new[83]	_	_
10-20	1706-1712	tremor	abstract[82]|abstract[83]	giv[82]|new[83]	_	_
10-21	1713-1714	,	abstract[82]	giv[82]	_	_
10-22	1715-1723	vascular	abstract[82]|abstract[84]	giv[82]|new[84]	_	_
10-23	1724-1736	parkinsonism	abstract[82]|abstract[84]	giv[82]|new[84]	_	_
10-24	1737-1740	and	abstract[82]	giv[82]	_	_
10-25	1741-1749	atypical	abstract[82]|abstract[86]	giv[82]|new[86]	_	_
10-26	1750-1762	parkinsonian	abstract[82]|place|abstract[86]	giv[82]|new|new[86]	_	_
10-27	1763-1772	syndromes	abstract[82]|abstract[86]	giv[82]|new[86]	_	_
10-28	1773-1781	manifest	_	_	_	_
10-29	1782-1783	.	_	_	_	_

#Text=Another difficulty to overcome , shared by all clinical assessment scales , is the mandatory presence of the specialist : this strongly influences the clinical management of the patient , as all the therapeutic decisions are restricted at the time of the single medical examination .
11-1	1784-1791	Another	abstract[87]	new[87]	coref	11-14[90_87]
11-2	1792-1802	difficulty	abstract[87]	new[87]	_	_
11-3	1803-1805	to	_	_	_	_
11-4	1806-1814	overcome	_	_	_	_
11-5	1815-1816	,	_	_	_	_
11-6	1817-1823	shared	_	_	_	_
11-7	1824-1826	by	_	_	_	_
11-8	1827-1830	all	abstract[89]	giv[89]	_	_
11-9	1831-1839	clinical	abstract[89]	giv[89]	_	_
11-10	1840-1850	assessment	abstract|abstract[89]	new|giv[89]	coref	18-25[188_0]
11-11	1851-1857	scales	abstract[89]	giv[89]	_	_
11-12	1858-1859	,	_	_	_	_
11-13	1860-1862	is	_	_	_	_
11-14	1863-1866	the	abstract[90]	giv[90]	ana	11-21[0_90]
11-15	1867-1876	mandatory	abstract[90]	giv[90]	_	_
11-16	1877-1885	presence	abstract[90]	giv[90]	_	_
11-17	1886-1888	of	abstract[90]	giv[90]	_	_
11-18	1889-1892	the	abstract[90]|person[91]	giv[90]|giv[91]	coref	23-35[250_91]
11-19	1893-1903	specialist	abstract[90]|person[91]	giv[90]|giv[91]	_	_
11-20	1904-1905	:	_	_	_	_
11-21	1906-1910	this	abstract	giv	coref	23-31[249_0]
11-22	1911-1919	strongly	_	_	_	_
11-23	1920-1930	influences	_	_	_	_
11-24	1931-1934	the	abstract[93]	new[93]	coref	24-10[256_93]
11-25	1935-1943	clinical	abstract[93]	new[93]	_	_
11-26	1944-1954	management	abstract[93]	new[93]	_	_
11-27	1955-1957	of	abstract[93]	new[93]	_	_
11-28	1958-1961	the	abstract[93]|person[94]	new[93]|giv[94]	coref	12-13[100_94]
11-29	1962-1969	patient	abstract[93]|person[94]	new[93]|giv[94]	_	_
11-30	1970-1971	,	_	_	_	_
11-31	1972-1974	as	_	_	_	_
11-32	1975-1978	all	abstract[95]	new[95]	_	_
11-33	1979-1982	the	abstract[95]	new[95]	_	_
11-34	1983-1994	therapeutic	abstract[95]	new[95]	_	_
11-35	1995-2004	decisions	abstract[95]	new[95]	_	_
11-36	2005-2008	are	_	_	_	_
11-37	2009-2019	restricted	_	_	_	_
11-38	2020-2022	at	_	_	_	_
11-39	2023-2026	the	_	_	_	_
11-40	2027-2031	time	_	_	_	_
11-41	2032-2034	of	_	_	_	_
11-42	2035-2038	the	abstract[96]	new[96]	coref	18-45[0_96]
11-43	2039-2045	single	abstract[96]	new[96]	_	_
11-44	2046-2053	medical	abstract[96]	new[96]	_	_
11-45	2054-2065	examination	abstract[96]	new[96]	_	_
11-46	2066-2067	.	_	_	_	_

#Text=However , during the time interval between two consecutive examinations , the patient ’s motor status may change significantly , out of the examiner ’s sight .
12-1	2068-2075	However	_	_	_	_
12-2	2076-2077	,	_	_	_	_
12-3	2078-2084	during	_	_	_	_
12-4	2085-2088	the	time[98]	new[98]	_	_
12-5	2089-2093	time	abstract|time[98]	giv|new[98]	_	_
12-6	2094-2102	interval	time[98]	new[98]	_	_
12-7	2103-2110	between	time[98]	new[98]	_	_
12-8	2111-2114	two	time[98]|event[99]	new[98]|new[99]	_	_
12-9	2115-2126	consecutive	time[98]|event[99]	new[98]|new[99]	_	_
12-10	2127-2139	examinations	time[98]|event[99]	new[98]|new[99]	_	_
12-11	2140-2141	,	_	_	_	_
12-12	2142-2145	the	abstract[102]	new[102]	coref	25-14[265_102]
12-13	2146-2153	patient	person[100]|abstract[102]	giv[100]|new[102]	coref	22-11[0_100]
12-14	2154-2156	’s	person[100]|abstract[102]	giv[100]|new[102]	_	_
12-15	2157-2162	motor	object|abstract[102]	giv|new[102]	coref	14-10
12-16	2163-2169	status	abstract[102]	new[102]	_	_
12-17	2170-2173	may	_	_	_	_
12-18	2174-2180	change	_	_	_	_
12-19	2181-2194	significantly	_	_	_	_
12-20	2195-2196	,	_	_	_	_
12-21	2197-2200	out	_	_	_	_
12-22	2201-2203	of	_	_	_	_
12-23	2204-2207	the	abstract[104]	new[104]	_	_
12-24	2208-2216	examiner	person[103]|abstract[104]	new[103]|new[104]	_	_
12-25	2217-2219	’s	person[103]|abstract[104]	new[103]|new[104]	_	_
12-26	2220-2225	sight	abstract[104]	new[104]	_	_
12-27	2226-2227	.	_	_	_	_

#Text=The chance of monitoring any change of the impairment in PD subjects over time , possibly daily and in a domestic environment , could have a strong impact on the clinical management of the patients and , consequently , on the long-term costs for the healthcare system .
13-1	2228-2231	The	abstract[105]	new[105]	_	_
13-2	2232-2238	chance	abstract[105]	new[105]	_	_
13-3	2239-2241	of	_	_	_	_
13-4	2242-2252	monitoring	_	_	_	_
13-5	2253-2256	any	abstract[106]	new[106]	_	_
13-6	2257-2263	change	abstract[106]	new[106]	_	_
13-7	2264-2266	of	abstract[106]	new[106]	_	_
13-8	2267-2270	the	abstract[106]|abstract[107]	new[106]|giv[107]	coref	21-28[0_107]
13-9	2271-2281	impairment	abstract[106]|abstract[107]	new[106]|giv[107]	_	_
13-10	2282-2284	in	abstract[106]|abstract[107]	new[106]|giv[107]	_	_
13-11	2285-2287	PD	abstract[106]|abstract[107]|abstract|abstract[109]	new[106]|giv[107]|giv|new[109]	coref|coref|coref|coref	14-23[125_109]|14-25|14-23[125_109]|14-25
13-12	2288-2296	subjects	abstract[106]|abstract[107]|abstract[109]	new[106]|giv[107]|new[109]	_	_
13-13	2297-2301	over	abstract[106]|abstract[107]|abstract[109]	new[106]|giv[107]|new[109]	_	_
13-14	2302-2306	time	abstract[106]|abstract[107]|abstract[109]	new[106]|giv[107]|new[109]	_	_
13-15	2307-2308	,	_	_	_	_
13-16	2309-2317	possibly	_	_	_	_
13-17	2318-2323	daily	_	_	_	_
13-18	2324-2327	and	_	_	_	_
13-19	2328-2330	in	_	_	_	_
13-20	2331-2332	a	place[110]	new[110]	_	_
13-21	2333-2341	domestic	place[110]	new[110]	_	_
13-22	2342-2353	environment	place[110]	new[110]	_	_
13-23	2354-2355	,	_	_	_	_
13-24	2356-2361	could	_	_	_	_
13-25	2362-2366	have	_	_	_	_
13-26	2367-2368	a	abstract[111]	new[111]	_	_
13-27	2369-2375	strong	abstract[111]	new[111]	_	_
13-28	2376-2382	impact	abstract[111]	new[111]	_	_
13-29	2383-2385	on	abstract[111]	new[111]	_	_
13-30	2386-2389	the	abstract[111]|abstract[112]	new[111]|new[112]	_	_
13-31	2390-2398	clinical	abstract[111]|abstract[112]	new[111]|new[112]	_	_
13-32	2399-2409	management	abstract[111]|abstract[112]	new[111]|new[112]	_	_
13-33	2410-2412	of	abstract[111]|abstract[112]	new[111]|new[112]	_	_
13-34	2413-2416	the	abstract[111]|abstract[112]|person[113]	new[111]|new[112]|giv[113]	_	_
13-35	2417-2425	patients	abstract[111]|abstract[112]|person[113]	new[111]|new[112]|giv[113]	_	_
13-36	2426-2429	and	_	_	_	_
13-37	2430-2431	,	_	_	_	_
13-38	2432-2444	consequently	abstract[114]	new[114]	_	_
13-39	2445-2446	,	abstract[114]	new[114]	_	_
13-40	2447-2449	on	abstract[114]	new[114]	_	_
13-41	2450-2453	the	abstract[114]	new[114]	_	_
13-42	2454-2463	long-term	abstract[114]	new[114]	_	_
13-43	2464-2469	costs	abstract[114]	new[114]	_	_
13-44	2470-2473	for	abstract[114]	new[114]	_	_
13-45	2474-2477	the	abstract[114]|abstract[116]	new[114]|new[116]	_	_
13-46	2478-2488	healthcare	abstract[114]|abstract|abstract[116]	new[114]|giv|new[116]	_	_
13-47	2489-2495	system	abstract[114]|abstract[116]	new[114]|new[116]	_	_
13-48	2496-2497	.	_	_	_	_

#Text=In an attempt to address these challenges and quantify motor symptoms , motion analysis studies have played a growing role in managing subjects with PD , exploring kinematic variables on gait ; tremor ; bradykinesia and rigidity .
14-1	2498-2500	In	_	_	_	_
14-2	2501-2503	an	abstract[117]	new[117]	_	_
14-3	2504-2511	attempt	abstract[117]	new[117]	_	_
14-4	2512-2514	to	_	_	_	_
14-5	2515-2522	address	_	_	_	_
14-6	2523-2528	these	abstract[118]	giv[118]	_	_
14-7	2529-2539	challenges	abstract[118]	giv[118]	_	_
14-8	2540-2543	and	_	_	_	_
14-9	2544-2552	quantify	_	_	_	_
14-10	2553-2558	motor	object|abstract[120]	giv|giv[120]	coref|coref	16-29|16-29
14-11	2559-2567	symptoms	abstract[120]	giv[120]	_	_
14-12	2568-2569	,	_	_	_	_
14-13	2570-2576	motion	abstract|abstract[123]	new|new[123]	coref|coref	15-9|15-9
14-14	2577-2585	analysis	abstract|abstract[123]	new|new[123]	coref	15-9[137_0]
14-15	2586-2593	studies	abstract[123]	new[123]	_	_
14-16	2594-2598	have	_	_	_	_
14-17	2599-2605	played	_	_	_	_
14-18	2606-2607	a	abstract[124]	new[124]	_	_
14-19	2608-2615	growing	abstract[124]	new[124]	_	_
14-20	2616-2620	role	abstract[124]	new[124]	_	_
14-21	2621-2623	in	_	_	_	_
14-22	2624-2632	managing	_	_	_	_
14-23	2633-2641	subjects	abstract[125]	giv[125]	coref	25-18[267_125]
14-24	2642-2646	with	abstract[125]	giv[125]	_	_
14-25	2647-2649	PD	abstract[125]|abstract	giv[125]|giv	coref	17-15
14-26	2650-2651	,	_	_	_	_
14-27	2652-2661	exploring	_	_	_	_
14-28	2662-2671	kinematic	abstract[127]	new[127]	_	_
14-29	2672-2681	variables	abstract[127]	new[127]	_	_
14-30	2682-2684	on	_	_	_	_
14-31	2685-2689	gait	abstract	new	appos	14-33
14-32	2690-2691	;	_	_	_	_
14-33	2692-2698	tremor	abstract	giv	_	_
14-34	2699-2700	;	_	_	_	_
14-35	2701-2713	bradykinesia	abstract|abstract[131]	giv|new[131]	ana|ana	15-13[0_131]|15-13[0_131]
14-36	2714-2717	and	abstract[131]	new[131]	_	_
14-37	2718-2726	rigidity	abstract[131]|abstract	new[131]|new	_	_
14-38	2727-2728	.	_	_	_	_

#Text=Motion capture systems are the reference standard for motion analysis , but they are expensive and non-portable , so their use is limited to laboratory environments and scientific research rather than to a routine clinical use .
15-1	2729-2735	Motion	person	new	_	_
15-2	2736-2743	capture	_	_	_	_
15-3	2744-2751	systems	abstract	new	ana	15-20
15-4	2752-2755	are	_	_	_	_
15-5	2756-2759	the	abstract[135]	new[135]	_	_
15-6	2760-2769	reference	abstract[135]	new[135]	_	_
15-7	2770-2778	standard	abstract[135]	new[135]	_	_
15-8	2779-2782	for	abstract[135]	new[135]	_	_
15-9	2783-2789	motion	abstract[135]|abstract|abstract[137]	new[135]|giv|giv[137]	coref|coref	17-10[155_137]|17-10[155_137]
15-10	2790-2798	analysis	abstract[135]|abstract[137]	new[135]|giv[137]	_	_
15-11	2799-2800	,	_	_	_	_
15-12	2801-2804	but	_	_	_	_
15-13	2805-2809	they	abstract	giv	_	_
15-14	2810-2813	are	_	_	_	_
15-15	2814-2823	expensive	_	_	_	_
15-16	2824-2827	and	_	_	_	_
15-17	2828-2840	non-portable	_	_	_	_
15-18	2841-2842	,	_	_	_	_
15-19	2843-2845	so	_	_	_	_
15-20	2846-2851	their	abstract|abstract[140]	giv|new[140]	coref|coref	17-35[167_0]|17-35[167_0]
15-21	2852-2855	use	abstract[140]	new[140]	_	_
15-22	2856-2858	is	_	_	_	_
15-23	2859-2866	limited	_	_	_	_
15-24	2867-2869	to	_	_	_	_
15-25	2870-2880	laboratory	place|place[142]	new|new[142]	_	_
15-26	2881-2893	environments	place[142]	new[142]	_	_
15-27	2894-2897	and	_	_	_	_
15-28	2898-2908	scientific	abstract[143]	new[143]	_	_
15-29	2909-2917	research	abstract[143]	new[143]	_	_
15-30	2918-2924	rather	_	_	_	_
15-31	2925-2929	than	_	_	_	_
15-32	2930-2932	to	_	_	_	_
15-33	2933-2934	a	abstract[144]	new[144]	coref	17-23[160_144]
15-34	2935-2942	routine	abstract[144]	new[144]	_	_
15-35	2943-2951	clinical	abstract[144]	new[144]	_	_
15-36	2952-2955	use	abstract[144]	new[144]	_	_
15-37	2956-2957	.	_	_	_	_

#Text=Therefore , in order to overcome these hurdles , it is urgent to find automatic and cost-effective solutions , capable of providing accurate and objective kinematic measures of motor performance and automatic scores that are well correlated to the standard clinical ones .
16-1	2958-2967	Therefore	_	_	_	_
16-2	2968-2969	,	_	_	_	_
16-3	2970-2972	in	_	_	_	_
16-4	2973-2978	order	_	_	_	_
16-5	2979-2981	to	_	_	_	_
16-6	2982-2990	overcome	_	_	_	_
16-7	2991-2996	these	abstract[145]	giv[145]	_	_
16-8	2997-3004	hurdles	abstract[145]	giv[145]	_	_
16-9	3005-3006	,	_	_	_	_
16-10	3007-3009	it	abstract	new	cata	16-10[0_147]
16-11	3010-3012	is	_	_	_	_
16-12	3013-3019	urgent	_	_	_	_
16-13	3020-3022	to	abstract[147]	new[147]	_	_
16-14	3023-3027	find	abstract[147]	new[147]	_	_
16-15	3028-3037	automatic	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
16-16	3038-3041	and	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
16-17	3042-3056	cost-effective	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
16-18	3057-3066	solutions	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
16-19	3067-3068	,	_	_	_	_
16-20	3069-3076	capable	_	_	_	_
16-21	3077-3079	of	_	_	_	_
16-22	3080-3089	providing	_	_	_	_
16-23	3090-3098	accurate	_	_	_	_
16-24	3099-3102	and	_	_	_	_
16-25	3103-3112	objective	abstract	new	coref|none	18-22[187_0]|16-25[0_187]
16-26	3113-3122	kinematic	abstract[149]	new[149]	_	_
16-27	3123-3131	measures	abstract[149]	new[149]	_	_
16-28	3132-3134	of	abstract[149]	new[149]	_	_
16-29	3135-3140	motor	abstract[149]|object|event[151]	new[149]|giv|new[151]	coref|coref	18-44|18-44
16-30	3141-3152	performance	abstract[149]|event[151]	new[149]|new[151]	_	_
16-31	3153-3156	and	abstract[149]	new[149]	_	_
16-32	3157-3166	automatic	abstract[149]|abstract[152]	new[149]|new[152]	_	_
16-33	3167-3173	scores	abstract[149]|abstract[152]	new[149]|new[152]	_	_
16-34	3174-3178	that	_	_	_	_
16-35	3179-3182	are	_	_	_	_
16-36	3183-3187	well	_	_	_	_
16-37	3188-3198	correlated	_	_	_	_
16-38	3199-3201	to	_	_	_	_
16-39	3202-3205	the	object[153]	new[153]	coref	18-30[189_153]
16-40	3206-3214	standard	object[153]	new[153]	_	_
16-41	3215-3223	clinical	object[153]	new[153]	_	_
16-42	3224-3228	ones	object[153]	new[153]	_	_
16-43	3229-3230	.	_	_	_	_

#Text=Recently , various technological approaches have been proposed for the analysis of movement in PD , including wearable sensor networks based on the use of inertial measurement units ( IMUs ) , smartphones and active vision systems based on new low-cost RGB-Depth optical devices such as Microsoft Kinect® ( Microsoft Corporation , Redmond , WA , USA ) and Intel RealSense® SR300 ( Intel Corporation , Santa Clara , CA , USA)[26 ] .
17-1	3231-3239	Recently	_	_	_	_
17-2	3240-3241	,	_	_	_	_
17-3	3242-3249	various	abstract[154]	new[154]	_	_
17-4	3250-3263	technological	abstract[154]	new[154]	_	_
17-5	3264-3274	approaches	abstract[154]	new[154]	_	_
17-6	3275-3279	have	_	_	_	_
17-7	3280-3284	been	_	_	_	_
17-8	3285-3293	proposed	_	_	_	_
17-9	3294-3297	for	_	_	_	_
17-10	3298-3301	the	abstract[155]	giv[155]	_	_
17-11	3302-3310	analysis	abstract[155]	giv[155]	_	_
17-12	3311-3313	of	abstract[155]	giv[155]	_	_
17-13	3314-3322	movement	abstract[155]|abstract[156]	giv[155]|giv[156]	_	_
17-14	3323-3325	in	abstract[155]|abstract[156]	giv[155]|giv[156]	_	_
17-15	3326-3328	PD	abstract[155]|abstract[156]|abstract	giv[155]|giv[156]|giv	coref	25-18
17-16	3329-3330	,	abstract[155]	giv[155]	_	_
17-17	3331-3340	including	abstract[155]	giv[155]	_	_
17-18	3341-3349	wearable	abstract[155]|object[159]	giv[155]|new[159]	_	_
17-19	3350-3356	sensor	abstract[155]|object|object[159]	giv[155]|new|new[159]	coref	19-27
17-20	3357-3365	networks	abstract[155]|object[159]	giv[155]|new[159]	_	_
17-21	3366-3371	based	_	_	_	_
17-22	3372-3374	on	_	_	_	_
17-23	3375-3378	the	abstract[160]	giv[160]	coref	21-33[231_160]
17-24	3379-3382	use	abstract[160]	giv[160]	_	_
17-25	3383-3385	of	abstract[160]	giv[160]	_	_
17-26	3386-3394	inertial	abstract[160]|abstract|object[163]	giv[160]|new|new[163]	_	_
17-27	3395-3406	measurement	abstract[160]|event|object[163]	giv[160]|new|new[163]	_	_
17-28	3407-3412	units	abstract[160]|object[163]	giv[160]|new[163]	_	_
17-29	3413-3414	(	_	_	_	_
17-30	3415-3419	IMUs	abstract	new	_	_
17-31	3420-3421	)	_	_	_	_
17-32	3422-3423	,	_	_	_	_
17-33	3424-3435	smartphones	object	new	_	_
17-34	3436-3439	and	_	_	_	_
17-35	3440-3446	active	abstract[167]	giv[167]	_	_
17-36	3447-3453	vision	abstract|abstract[167]	new|giv[167]	coref	19-7
17-37	3454-3461	systems	abstract[167]	giv[167]	_	_
17-38	3462-3467	based	_	_	_	_
17-39	3468-3470	on	_	_	_	_
17-40	3471-3474	new	object[168]	new[168]	_	_
17-41	3475-3483	low-cost	object[168]	new[168]	_	_
17-42	3484-3493	RGB-Depth	object[168]	new[168]	_	_
17-43	3494-3501	optical	object[168]	new[168]	_	_
17-44	3502-3509	devices	object[168]	new[168]	_	_
17-45	3510-3514	such	object[168]	new[168]	_	_
17-46	3515-3517	as	object[168]	new[168]	_	_
17-47	3518-3527	Microsoft	object[168]|organization|object[170]	new[168]|new|new[170]	coref|coref	17-50|17-50
17-48	3528-3535	Kinect®	object[168]|object[170]	new[168]|new[170]	_	_
17-49	3536-3537	(	object[168]	new[168]	_	_
17-50	3538-3547	Microsoft	object[168]|organization	new[168]|giv	_	_
17-51	3548-3559	Corporation	object[168]	new[168]	_	_
17-52	3560-3561	,	object[168]	new[168]	_	_
17-53	3562-3569	Redmond	object[168]	new[168]	_	_
17-54	3570-3571	,	object[168]	new[168]	_	_
17-55	3572-3574	WA	object[168]	new[168]	_	_
17-56	3575-3576	,	object[168]	new[168]	_	_
17-57	3577-3580	USA	object[168]|place	new[168]|new	_	_
17-58	3581-3582	)	object[168]	new[168]	_	_
17-59	3583-3586	and	object[168]	new[168]	_	_
17-60	3587-3592	Intel	object[168]|organization|object[175]	new[168]|new|new[175]	coref|appos|coref|appos	17-64|17-64[178_175]|17-64|17-64[178_175]
17-61	3593-3603	RealSense®	object[168]|abstract|object[175]	new[168]|new|new[175]	_	_
17-62	3604-3609	SR300	object[168]|object[175]	new[168]|new[175]	_	_
17-63	3610-3611	(	_	_	_	_
17-64	3612-3617	Intel	organization|organization[177]|object[178]	giv|new[177]|giv[178]	_	_
17-65	3618-3629	Corporation	organization[177]|object[178]	new[177]|giv[178]	_	_
17-66	3630-3631	,	object[178]	giv[178]	_	_
17-67	3632-3637	Santa	object[178]|place[179]	giv[178]|new[179]	_	_
17-68	3638-3643	Clara	object[178]|place[179]	giv[178]|new[179]	_	_
17-69	3644-3645	,	object[178]	giv[178]	_	_
17-70	3646-3648	CA	object[178]|place	giv[178]|new	_	_
17-71	3649-3650	,	object[178]	giv[178]	_	_
17-72	3651-3658	USA)[26	object[178]|place	giv[178]|new	_	_
17-73	3659-3660	]	_	_	_	_
17-74	3661-3662	.	_	_	_	_

#Text=On the basis of these considerations , we propose the integration of two different sensor-based subsystems as a single solution for the objective , accurate and automated assessment of some standard tasks for the upper and lower limbs , as defined in the motor examination section ( Section 3 ) of UPDRS .
18-1	3663-3665	On	_	_	_	_
18-2	3666-3669	the	abstract[182]	new[182]	_	_
18-3	3670-3675	basis	abstract[182]	new[182]	_	_
18-4	3676-3678	of	abstract[182]	new[182]	_	_
18-5	3679-3684	these	abstract[182]|abstract[183]	new[182]|new[183]	_	_
18-6	3685-3699	considerations	abstract[182]|abstract[183]	new[182]|new[183]	_	_
18-7	3700-3701	,	_	_	_	_
18-8	3702-3704	we	person	acc	_	_
18-9	3705-3712	propose	_	_	_	_
18-10	3713-3716	the	abstract[185]	new[185]	_	_
18-11	3717-3728	integration	abstract[185]	new[185]	_	_
18-12	3729-3731	of	abstract[185]	new[185]	_	_
18-13	3732-3735	two	abstract[185]|abstract[186]	new[185]|new[186]	_	_
18-14	3736-3745	different	abstract[185]|abstract[186]	new[185]|new[186]	_	_
18-15	3746-3758	sensor-based	abstract[185]|abstract[186]	new[185]|new[186]	_	_
18-16	3759-3769	subsystems	abstract[185]|abstract[186]	new[185]|new[186]	_	_
18-17	3770-3772	as	abstract[185]|abstract[186]	new[185]|new[186]	_	_
18-18	3773-3774	a	abstract[185]|abstract[186]	new[185]|new[186]	_	_
18-19	3775-3781	single	abstract[185]|abstract[186]	new[185]|new[186]	_	_
18-20	3782-3790	solution	abstract[185]|abstract[186]	new[185]|new[186]	_	_
18-21	3791-3794	for	abstract[185]|abstract[186]	new[185]|new[186]	_	_
18-22	3795-3798	the	abstract[185]|abstract[186]|abstract[187]	new[185]|new[186]|new[187]	_	_
18-23	3799-3808	objective	abstract[185]|abstract[186]|abstract[187]	new[185]|new[186]|new[187]	_	_
18-24	3809-3810	,	_	_	_	_
18-25	3811-3819	accurate	abstract[188]	giv[188]	_	_
18-26	3820-3823	and	abstract[188]	giv[188]	_	_
18-27	3824-3833	automated	abstract[188]	giv[188]	_	_
18-28	3834-3844	assessment	abstract[188]	giv[188]	_	_
18-29	3845-3847	of	abstract[188]	giv[188]	_	_
18-30	3848-3852	some	abstract[188]|abstract[189]	giv[188]|giv[189]	coref	19-14[201_189]
18-31	3853-3861	standard	abstract[188]|abstract[189]	giv[188]|giv[189]	_	_
18-32	3862-3867	tasks	abstract[188]|abstract[189]	giv[188]|giv[189]	_	_
18-33	3868-3871	for	abstract[188]|abstract[189]	giv[188]|giv[189]	_	_
18-34	3872-3875	the	abstract[188]|abstract[189]|object[190]	giv[188]|giv[189]|new[190]	coref	19-19[202_190]
18-35	3876-3881	upper	abstract[188]|abstract[189]|object[190]	giv[188]|giv[189]|new[190]	_	_
18-36	3882-3885	and	abstract[188]|abstract[189]|object[190]	giv[188]|giv[189]|new[190]	_	_
18-37	3886-3891	lower	abstract[188]|abstract[189]|object[190]	giv[188]|giv[189]|new[190]	_	_
18-38	3892-3897	limbs	abstract[188]|abstract[189]|object[190]	giv[188]|giv[189]|new[190]	_	_
18-39	3898-3899	,	_	_	_	_
18-40	3900-3902	as	_	_	_	_
18-41	3903-3910	defined	_	_	_	_
18-42	3911-3913	in	_	_	_	_
18-43	3914-3917	the	abstract[193]	new[193]	appos	18-48[194_193]
18-44	3918-3923	motor	object|abstract[193]	giv|new[193]	coref	19-15
18-45	3924-3935	examination	abstract|abstract[193]	giv|new[193]	_	_
18-46	3936-3943	section	abstract[193]	new[193]	_	_
18-47	3944-3945	(	_	_	_	_
18-48	3946-3953	Section	abstract[194]	giv[194]	coref	20-30[221_194]
18-49	3954-3955	3	abstract[194]	giv[194]	_	_
18-50	3956-3957	)	_	_	_	_
18-51	3958-3960	of	_	_	_	_
18-52	3961-3966	UPDRS	organization	giv	coref	20-13
18-53	3967-3968	.	_	_	_	_

#Text=The first component is an active vision system dedicated to the analysis of the motor tasks related to upper limbs ; the second applies a body sensor network ( BSN ) approach with wireless wearable sensors for the analysis of the lower limb tasks .
19-1	3969-3972	The	abstract[196]	new[196]	coref	19-5[198_196]
19-2	3973-3978	first	abstract[196]	new[196]	_	_
19-3	3979-3988	component	abstract[196]	new[196]	_	_
19-4	3989-3991	is	_	_	_	_
19-5	3992-3994	an	abstract[198]	giv[198]	coref	21-23[227_198]
19-6	3995-4001	active	abstract[198]	giv[198]	_	_
19-7	4002-4008	vision	abstract|abstract[198]	giv|giv[198]	_	_
19-8	4009-4015	system	abstract[198]	giv[198]	_	_
19-9	4016-4025	dedicated	_	_	_	_
19-10	4026-4028	to	_	_	_	_
19-11	4029-4032	the	abstract[199]	new[199]	_	_
19-12	4033-4041	analysis	abstract[199]	new[199]	_	_
19-13	4042-4044	of	abstract[199]	new[199]	_	_
19-14	4045-4048	the	abstract[199]|abstract[201]	new[199]|giv[201]	coref	19-41[212_201]
19-15	4049-4054	motor	abstract[199]|object|abstract[201]	new[199]|giv|giv[201]	coref	23-20
19-16	4055-4060	tasks	abstract[199]|abstract[201]	new[199]|giv[201]	_	_
19-17	4061-4068	related	_	_	_	_
19-18	4069-4071	to	_	_	_	_
19-19	4072-4077	upper	object[202]	giv[202]	_	_
19-20	4078-4083	limbs	object[202]	giv[202]	_	_
19-21	4084-4085	;	_	_	_	_
19-22	4086-4089	the	_	_	_	_
19-23	4090-4096	second	_	_	_	_
19-24	4097-4104	applies	_	_	_	_
19-25	4105-4106	a	object[205]	new[205]	_	_
19-26	4107-4111	body	organization|object[205]	new|new[205]	_	_
19-27	4112-4118	sensor	person|object[205]	giv|new[205]	_	_
19-28	4119-4126	network	object[205]	new[205]	_	_
19-29	4127-4128	(	_	_	_	_
19-30	4129-4132	BSN	organization	new	_	_
19-31	4133-4134	)	_	_	_	_
19-32	4135-4143	approach	abstract[207]	new[207]	coref	24-6[255_207]
19-33	4144-4148	with	abstract[207]	new[207]	_	_
19-34	4149-4157	wireless	abstract[207]|object|object[209]	new[207]|new|new[209]	_	_
19-35	4158-4166	wearable	abstract[207]|object[209]	new[207]|new[209]	_	_
19-36	4167-4174	sensors	abstract[207]|object[209]	new[207]|new[209]	_	_
19-37	4175-4178	for	abstract[207]|object[209]	new[207]|new[209]	_	_
19-38	4179-4182	the	abstract[207]|object[209]|abstract[210]	new[207]|new[209]|new[210]	_	_
19-39	4183-4191	analysis	abstract[207]|object[209]|abstract[210]	new[207]|new[209]|new[210]	_	_
19-40	4192-4194	of	abstract[207]|object[209]|abstract[210]	new[207]|new[209]|new[210]	_	_
19-41	4195-4198	the	abstract[207]|object[209]|abstract[210]|abstract[212]	new[207]|new[209]|new[210]|giv[212]	coref	22-17[238_212]
19-42	4199-4204	lower	abstract[207]|object[209]|abstract[210]|abstract[212]	new[207]|new[209]|new[210]|giv[212]	_	_
19-43	4205-4209	limb	abstract[207]|object[209]|abstract[210]|object|abstract[212]	new[207]|new[209]|new[210]|new|giv[212]	_	_
19-44	4210-4215	tasks	abstract[207]|object[209]|abstract[210]|abstract[212]	new[207]|new[209]|new[210]|giv[212]	_	_
19-45	4216-4217	.	_	_	_	_

#Text=The technical details of both and the validation of their accuracy as UPDRS automatic scoring systems have been already presented in previous works and will be briefly summarized in the Materials and Methods section .
20-1	4218-4221	The	abstract[213]|abstract[214]	new[213]|new[214]	_	_
20-2	4222-4231	technical	abstract[213]|abstract[214]	new[213]|new[214]	_	_
20-3	4232-4239	details	abstract[213]|abstract[214]	new[213]|new[214]	_	_
20-4	4240-4242	of	abstract[214]	new[214]	_	_
20-5	4243-4247	both	abstract[214]|abstract[215]	new[214]|new[215]	_	_
20-6	4248-4251	and	abstract[214]|abstract[215]	new[214]|new[215]	_	_
20-7	4252-4255	the	abstract[214]|abstract[215]	new[214]|new[215]	_	_
20-8	4256-4266	validation	abstract[214]|abstract[215]	new[214]|new[215]	_	_
20-9	4267-4269	of	abstract[214]|abstract[215]	new[214]|new[215]	_	_
20-10	4270-4275	their	abstract[214]|abstract[215]|abstract[216]	new[214]|new[215]|new[216]	_	_
20-11	4276-4284	accuracy	abstract[214]|abstract[215]|abstract[216]	new[214]|new[215]|new[216]	_	_
20-12	4285-4287	as	abstract[214]|abstract[215]|abstract[216]	new[214]|new[215]|new[216]	_	_
20-13	4288-4293	UPDRS	abstract[214]|abstract[215]|abstract[216]|abstract	new[214]|new[215]|new[216]|giv	coref	22-17
20-14	4294-4303	automatic	abstract[214]|abstract[215]|abstract[216]	new[214]|new[215]|new[216]	_	_
20-15	4304-4311	scoring	abstract[214]|abstract[215]|abstract[216]	new[214]|new[215]|new[216]	_	_
20-16	4312-4319	systems	abstract[214]|abstract[215]|abstract[216]	new[214]|new[215]|new[216]	_	_
20-17	4320-4324	have	_	_	_	_
20-18	4325-4329	been	_	_	_	_
20-19	4330-4337	already	_	_	_	_
20-20	4338-4347	presented	_	_	_	_
20-21	4348-4350	in	_	_	_	_
20-22	4351-4359	previous	abstract[218]	new[218]	_	_
20-23	4360-4365	works	abstract[218]	new[218]	_	_
20-24	4366-4369	and	_	_	_	_
20-25	4370-4374	will	_	_	_	_
20-26	4375-4377	be	_	_	_	_
20-27	4378-4385	briefly	_	_	_	_
20-28	4386-4396	summarized	_	_	_	_
20-29	4397-4399	in	_	_	_	_
20-30	4400-4403	the	abstract[221]	giv[221]	_	_
20-31	4404-4413	Materials	substance|abstract[221]	new|giv[221]	_	_
20-32	4414-4417	and	abstract[221]	giv[221]	_	_
20-33	4418-4425	Methods	object|abstract[221]	new|giv[221]	_	_
20-34	4426-4433	section	abstract[221]	giv[221]	_	_
20-35	4434-4435	.	_	_	_	_

#Text=A gesture-based human machine interface has been developed as part of the solution , to simplify the interaction and the self-management of the system by people with impairment , in view of a possible use at home .
21-1	4436-4437	A	abstract[223]	new[223]	_	_
21-2	4438-4451	gesture-based	abstract[223]	new[223]	_	_
21-3	4452-4457	human	abstract[223]	new[223]	_	_
21-4	4458-4465	machine	object|abstract[223]	new|new[223]	_	_
21-5	4466-4475	interface	abstract[223]	new[223]	_	_
21-6	4476-4479	has	_	_	_	_
21-7	4480-4484	been	_	_	_	_
21-8	4485-4494	developed	_	_	_	_
21-9	4495-4497	as	_	_	_	_
21-10	4498-4502	part	_	_	_	_
21-11	4503-4505	of	_	_	_	_
21-12	4506-4509	the	abstract[224]	new[224]	_	_
21-13	4510-4518	solution	abstract[224]	new[224]	_	_
21-14	4519-4520	,	_	_	_	_
21-15	4521-4523	to	_	_	_	_
21-16	4524-4532	simplify	_	_	_	_
21-17	4533-4536	the	event[225]	new[225]	_	_
21-18	4537-4548	interaction	event[225]	new[225]	_	_
21-19	4549-4552	and	_	_	_	_
21-20	4553-4556	the	abstract[226]	new[226]	_	_
21-21	4557-4572	self-management	abstract[226]	new[226]	_	_
21-22	4573-4575	of	abstract[226]	new[226]	_	_
21-23	4576-4579	the	abstract[226]|abstract[227]	new[226]|giv[227]	coref	22-1[233_227]
21-24	4580-4586	system	abstract[226]|abstract[227]	new[226]|giv[227]	_	_
21-25	4587-4589	by	abstract[226]|abstract[227]	new[226]|giv[227]	_	_
21-26	4590-4596	people	abstract[226]|abstract[227]|person[228]	new[226]|giv[227]|new[228]	_	_
21-27	4597-4601	with	abstract[226]|abstract[227]|person[228]	new[226]|giv[227]|new[228]	_	_
21-28	4602-4612	impairment	abstract[226]|abstract[227]|person[228]|abstract	new[226]|giv[227]|new[228]|giv	_	_
21-29	4613-4614	,	_	_	_	_
21-30	4615-4617	in	_	_	_	_
21-31	4618-4622	view	abstract[230]	new[230]	_	_
21-32	4623-4625	of	abstract[230]	new[230]	_	_
21-33	4626-4627	a	abstract[230]|abstract[231]	new[230]|giv[231]	_	_
21-34	4628-4636	possible	abstract[230]|abstract[231]	new[230]|giv[231]	_	_
21-35	4637-4640	use	abstract[230]|abstract[231]	new[230]|giv[231]	_	_
21-36	4641-4643	at	abstract[230]|abstract[231]	new[230]|giv[231]	_	_
21-37	4644-4648	home	abstract[230]|abstract[231]|place	new[230]|giv[231]|new	_	_
21-38	4649-4650	.	_	_	_	_

#Text=The system is able to analyze and automatically score the patient movements during the performance of UPDRS tasks .
22-1	4651-4654	The	abstract[233]	giv[233]	coref	24-24[261_233]
22-2	4655-4661	system	abstract[233]	giv[233]	_	_
22-3	4662-4664	is	_	_	_	_
22-4	4665-4669	able	_	_	_	_
22-5	4670-4672	to	_	_	_	_
22-6	4673-4680	analyze	_	_	_	_
22-7	4681-4684	and	_	_	_	_
22-8	4685-4698	automatically	_	_	_	_
22-9	4699-4704	score	_	_	_	_
22-10	4705-4708	the	abstract[235]	new[235]	_	_
22-11	4709-4716	patient	person|abstract[235]	giv|new[235]	coref	24-14[257_0]
22-12	4717-4726	movements	abstract[235]	new[235]	_	_
22-13	4727-4733	during	_	_	_	_
22-14	4734-4737	the	event[236]	new[236]	ana	23-4[0_236]
22-15	4738-4749	performance	event[236]	new[236]	_	_
22-16	4750-4752	of	event[236]	new[236]	_	_
22-17	4753-4758	UPDRS	event[236]|organization|abstract[238]	new[236]|giv|giv[238]	_	_
22-18	4759-4764	tasks	event[236]|abstract[238]	new[236]|giv[238]	_	_
22-19	4765-4766	.	_	_	_	_

#Text=In addition , it archives in the Cloud the kinematic data , the score and the video of each motor performance , guaranteeing the remote supervision by clinicians and overcoming the mandatory presence of the specialist during the execution of the motor activities .
23-1	4767-4769	In	_	_	_	_
23-2	4770-4778	addition	_	_	_	_
23-3	4779-4780	,	_	_	_	_
23-4	4781-4783	it	event	giv	coref	23-19[245_0]
23-5	4784-4792	archives	_	_	_	_
23-6	4793-4795	in	_	_	_	_
23-7	4796-4799	the	person[240]	new[240]	_	_
23-8	4800-4805	Cloud	person[240]	new[240]	_	_
23-9	4806-4809	the	abstract[241]	new[241]	appos	23-13[242_241]
23-10	4810-4819	kinematic	abstract[241]	new[241]	_	_
23-11	4820-4824	data	abstract[241]	new[241]	_	_
23-12	4825-4826	,	_	_	_	_
23-13	4827-4830	the	abstract[242]	giv[242]	_	_
23-14	4831-4836	score	abstract[242]	giv[242]	_	_
23-15	4837-4840	and	_	_	_	_
23-16	4841-4844	the	abstract[243]	giv[243]	_	_
23-17	4845-4850	video	abstract[243]	giv[243]	_	_
23-18	4851-4853	of	abstract[243]	giv[243]	_	_
23-19	4854-4858	each	abstract[243]|event[245]	giv[243]|giv[245]	_	_
23-20	4859-4864	motor	abstract[243]|object|event[245]	giv[243]|giv|giv[245]	coref	23-42
23-21	4865-4876	performance	abstract[243]|event[245]	giv[243]|giv[245]	_	_
23-22	4877-4878	,	_	_	_	_
23-23	4879-4891	guaranteeing	_	_	_	_
23-24	4892-4895	the	abstract[247]	new[247]	_	_
23-25	4896-4902	remote	object|abstract[247]	new|new[247]	_	_
23-26	4903-4914	supervision	abstract[247]	new[247]	_	_
23-27	4915-4917	by	abstract[247]	new[247]	_	_
23-28	4918-4928	clinicians	abstract[247]|person	new[247]|new	_	_
23-29	4929-4932	and	_	_	_	_
23-30	4933-4943	overcoming	_	_	_	_
23-31	4944-4947	the	abstract[249]	giv[249]	_	_
23-32	4948-4957	mandatory	abstract[249]	giv[249]	_	_
23-33	4958-4966	presence	abstract[249]	giv[249]	_	_
23-34	4967-4969	of	abstract[249]	giv[249]	_	_
23-35	4970-4973	the	abstract[249]|person[250]	giv[249]|giv[250]	_	_
23-36	4974-4984	specialist	abstract[249]|person[250]	giv[249]|giv[250]	_	_
23-37	4985-4991	during	_	_	_	_
23-38	4992-4995	the	event[251]	new[251]	_	_
23-39	4996-5005	execution	event[251]	new[251]	_	_
23-40	5006-5008	of	event[251]	new[251]	_	_
23-41	5009-5012	the	event[251]|abstract[253]	new[251]|new[253]	_	_
23-42	5013-5018	motor	event[251]|object|abstract[253]	new[251]|giv|new[253]	_	_
23-43	5019-5029	activities	event[251]|abstract[253]	new[251]|new[253]	_	_
23-44	5030-5031	.	_	_	_	_

#Text=Finally , in view of a decentralized approach to the clinical management of the patient , the issue of acceptability and usability of the integrated system has been evaluated through a standard questionnaire .
24-1	5032-5039	Finally	_	_	_	_
24-2	5040-5041	,	_	_	_	_
24-3	5042-5044	in	_	_	_	_
24-4	5045-5049	view	abstract[254]	new[254]	_	_
24-5	5050-5052	of	abstract[254]	new[254]	_	_
24-6	5053-5054	a	abstract[254]|abstract[255]	new[254]|giv[255]	coref	25-21[268_255]
24-7	5055-5068	decentralized	abstract[254]|abstract[255]	new[254]|giv[255]	_	_
24-8	5069-5077	approach	abstract[254]|abstract[255]	new[254]|giv[255]	_	_
24-9	5078-5080	to	abstract[254]|abstract[255]	new[254]|giv[255]	_	_
24-10	5081-5084	the	abstract[254]|abstract[255]|abstract[256]	new[254]|giv[255]|giv[256]	_	_
24-11	5085-5093	clinical	abstract[254]|abstract[255]|abstract[256]	new[254]|giv[255]|giv[256]	_	_
24-12	5094-5104	management	abstract[254]|abstract[255]|abstract[256]	new[254]|giv[255]|giv[256]	_	_
24-13	5105-5107	of	abstract[254]|abstract[255]|abstract[256]	new[254]|giv[255]|giv[256]	_	_
24-14	5108-5111	the	abstract[254]|abstract[255]|abstract[256]|person[257]	new[254]|giv[255]|giv[256]|giv[257]	_	_
24-15	5112-5119	patient	abstract[254]|abstract[255]|abstract[256]|person[257]	new[254]|giv[255]|giv[256]|giv[257]	_	_
24-16	5120-5121	,	_	_	_	_
24-17	5122-5125	the	abstract[258]	giv[258]	_	_
24-18	5126-5131	issue	abstract[258]	giv[258]	_	_
24-19	5132-5134	of	abstract[258]	giv[258]	_	_
24-20	5135-5148	acceptability	abstract[258]|abstract	giv[258]|new	_	_
24-21	5149-5152	and	abstract[258]	giv[258]	_	_
24-22	5153-5162	usability	abstract[258]|abstract[260]	giv[258]|new[260]	_	_
24-23	5163-5165	of	abstract[258]|abstract[260]	giv[258]|new[260]	_	_
24-24	5166-5169	the	abstract[258]|abstract[260]|abstract[261]	giv[258]|new[260]|giv[261]	coref	25-1[263_261]
24-25	5170-5180	integrated	abstract[258]|abstract[260]|abstract[261]	giv[258]|new[260]|giv[261]	_	_
24-26	5181-5187	system	abstract[258]|abstract[260]|abstract[261]	giv[258]|new[260]|giv[261]	_	_
24-27	5188-5191	has	_	_	_	_
24-28	5192-5196	been	_	_	_	_
24-29	5197-5206	evaluated	_	_	_	_
24-30	5207-5214	through	_	_	_	_
24-31	5215-5216	a	abstract[262]	new[262]	_	_
24-32	5217-5225	standard	abstract[262]	new[262]	_	_
24-33	5226-5239	questionnaire	abstract[262]	new[262]	_	_
24-34	5240-5241	.	_	_	_	_

#Text=The integrated system here presented is aimed at a more comprehensive evaluation of the neuro-motor status of PD subjects by a decentralized approach , and could represent a new example of an accurate , feasible and cost-effective strategy for the clinical management of PD .
25-1	5242-5245	The	abstract[263]	giv[263]	_	_
25-2	5246-5256	integrated	abstract[263]	giv[263]	_	_
25-3	5257-5263	system	abstract[263]	giv[263]	_	_
25-4	5264-5268	here	_	_	_	_
25-5	5269-5278	presented	_	_	_	_
25-6	5279-5281	is	_	_	_	_
25-7	5282-5287	aimed	_	_	_	_
25-8	5288-5290	at	_	_	_	_
25-9	5291-5292	a	abstract[264]	giv[264]	_	_
25-10	5293-5297	more	abstract[264]	giv[264]	_	_
25-11	5298-5311	comprehensive	abstract[264]	giv[264]	_	_
25-12	5312-5322	evaluation	abstract[264]	giv[264]	_	_
25-13	5323-5325	of	abstract[264]	giv[264]	_	_
25-14	5326-5329	the	abstract[264]|abstract[265]	giv[264]|giv[265]	_	_
25-15	5330-5341	neuro-motor	abstract[264]|abstract[265]	giv[264]|giv[265]	_	_
25-16	5342-5348	status	abstract[264]|abstract[265]	giv[264]|giv[265]	_	_
25-17	5349-5351	of	abstract[264]|abstract[265]	giv[264]|giv[265]	_	_
25-18	5352-5354	PD	abstract[264]|abstract[265]|abstract|abstract[267]	giv[264]|giv[265]|giv|giv[267]	coref|coref	25-44|25-44
25-19	5355-5363	subjects	abstract[264]|abstract[265]|abstract[267]	giv[264]|giv[265]|giv[267]	_	_
25-20	5364-5366	by	abstract[264]|abstract[265]	giv[264]|giv[265]	_	_
25-21	5367-5368	a	abstract[264]|abstract[265]|abstract[268]	giv[264]|giv[265]|giv[268]	_	_
25-22	5369-5382	decentralized	abstract[264]|abstract[265]|abstract[268]	giv[264]|giv[265]|giv[268]	_	_
25-23	5383-5391	approach	abstract[264]|abstract[265]|abstract[268]	giv[264]|giv[265]|giv[268]	_	_
25-24	5392-5393	,	_	_	_	_
25-25	5394-5397	and	_	_	_	_
25-26	5398-5403	could	_	_	_	_
25-27	5404-5413	represent	_	_	_	_
25-28	5414-5415	a	abstract[269]	new[269]	_	_
25-29	5416-5419	new	abstract[269]	new[269]	_	_
25-30	5420-5427	example	abstract[269]	new[269]	_	_
25-31	5428-5430	of	abstract[269]	new[269]	_	_
25-32	5431-5433	an	abstract[269]|abstract[270]	new[269]|new[270]	_	_
25-33	5434-5442	accurate	abstract[269]|abstract[270]	new[269]|new[270]	_	_
25-34	5443-5444	,	abstract[269]|abstract[270]	new[269]|new[270]	_	_
25-35	5445-5453	feasible	abstract[269]|abstract[270]	new[269]|new[270]	_	_
25-36	5454-5457	and	abstract[269]|abstract[270]	new[269]|new[270]	_	_
25-37	5458-5472	cost-effective	abstract[269]|abstract[270]	new[269]|new[270]	_	_
25-38	5473-5481	strategy	abstract[269]|abstract[270]	new[269]|new[270]	_	_
25-39	5482-5485	for	abstract[269]|abstract[270]	new[269]|new[270]	_	_
25-40	5486-5489	the	abstract[269]|abstract[270]|abstract[271]	new[269]|new[270]|new[271]	_	_
25-41	5490-5498	clinical	abstract[269]|abstract[270]|abstract[271]	new[269]|new[270]|new[271]	_	_
25-42	5499-5509	management	abstract[269]|abstract[270]|abstract[271]	new[269]|new[270]|new[271]	_	_
25-43	5510-5512	of	abstract[269]|abstract[270]|abstract[271]	new[269]|new[270]|new[271]	_	_
25-44	5513-5515	PD	abstract[269]|abstract[270]|abstract[271]|abstract	new[269]|new[270]|new[271]|giv	_	_
25-45	5516-5517	.	_	_	_	_
